Pasar al contenido principal

PAPEL DE TNF-A EN LA REGULACION DE LA CAPACIDAD REGENERATIVA MUSCULAR DE SUJETOS SANOS Y DE PACIENTES CON EPOC

SAF2011-26908

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2011
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario FUNDACIO INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MEDIQUES
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Do epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease?

  • Puig Vilanova, Ester, 1987-
  • Ausín Herrero, Pilar, 1974-
  • Martínez-Llorens, Juana Mª
  • Gea Guiral, Joaquim
  • Barreiro Portela, Esther
Muscle dysfunction is a major comorbidity in Chronic Obstructive Pulmonary Disease (COPD). Several biological mechanisms including epigenetic events regulate muscle mass and function in models of muscle atrophy. Investigations conducted so far have focused on the elucidation of biological mechanisms involved in muscle dysfunction in advanced COPD. We assessed whether the epigenetic profile may be altered in the vastus lateralis of patients with mild COPD, normal body composition, and mildly impaired muscle function and exercise capacity. In vastus lateralis (VL) of mild COPD patients with well-preserved body composition and in healthy age-matched controls, expression of DNA methylation, muscle-enriched microRNAs, histone acetyltransferases (HTAs) and deacetylases (HDACs), protein acetylation, small ubiquitin-related modifier (SUMO) ligases, and muscle structure were explored. All subjects were clinically evaluated. Compared to healthy controls, in the VL of mild COPD patients, muscle function and exercise capacity were moderately reduced, DNA methylation levels did not differ, miR-1 expression levels were increased and positively correlated with both forced expiratory volume in one second (FEV1) and quadriceps force, HDAC4 protein levels were increased, and muscle fiber types and sizes were not different. Moderate skeletal muscle dysfunction is a relevant feature in patients with mild COPD and preserved body composition. Several epigenetic events are differentially expressed in the limb muscles of these patients, probably as an attempt to counterbalance the underlying mechanisms that alter muscle function and mass. The study of patients at early stages of their disease is of interest as they are a target for timely therapeutic interventions that may slow down the course of the disease and prevent the deleterious effects of major comorbidities., This study has been supported by Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES); Fondo de Investigaciones Sanitarias (FIS) 11/02029; FIS 12/02534; SAF-2011-26908; 2009-SGR-393; Sociedad Española de Neumología y Cirugía Torácica (SEPAR) 2009; Fundació Catalana de Pneumologia (FUCAP) 2011; FUCAP 2012; and Marató TV3 (MTV3-07-1010) (Spain). Dr. Esther Barreiro was a recipient of the European Respiratory Society (ERS) COPD Research Award 2008
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Network medicine analysis of COPD multimorbidities

  • Grosdidier, Solène
  • Ferrer, Antoni-Lluc, 1942-
  • Faner, Rosa
  • Piñero González, Janet, 1977-
  • Roca, Josep
  • García Cosio, Borja
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Background: Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages between COPD and their associated diseases is of great interest. Methods: We developed a novel, unbiased, integrative network medicine approach for the analysis of the diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the study of 16 prevalent COPD multimorbidities identified by clinical experts. Results: Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their associated diseases in more detail, we identified known biological pathways involved in COPD, such as inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More interestingly, we found previously overlooked biological pathways that might contribute to explain COPD multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified proteins participating in COPD multimorbidities. Conclusions: The network medicine approach presented here allowed the identification of plausible molecular links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome, proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities., This work was supported by the Instituto de Salud Carlos III FEDER (CP10/00524 and PI13/00082), COMBIOMED and SAF2011-26908 grants
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Redox imbalance in lung cancer of patients with underlying chronic respiratory conditions

  • Mateu Jiménez, Mercè, 1990-
  • Sánchez-Font, Albert
  • Rodríguez-Fuster, Alberto
  • Aguiló Espases, Rafael
  • Pijuan Andujar, Lara
  • Fermoselle Pérez, Clara, 1985-
  • Gea Guiral, Joaquim
  • Curull Serrano, Víctor
  • Barreiro Portela, Esther
Chronic respiratory diseases such as obstructive pulmonary disease (COPD) and oxidative stress may underlie lung cancer (LC). We hypothesized that the profile of oxidative and antioxidant events may differ in lung tumors and blood compartments of patients with non-small cell LC (NSCLC) with and without COPD. Redox markers (immunoblotting, ELISA, chemiluminescence, 2D electrophoresis and proteomics) were analyzed in blood samples of 17 control subjects and 80 LC patients (59 LC-COPD and 21 LC) and lung specimens (tumor and nontumor) from those undergoing thoracotomy (35 patients: 23 LC-COPD and 12 LC). As smoking history was more prevalent in LC-COPD patients, these were further analyzed post hoc as heavy and moderate smokers (cutoff, 60 pack-years). Malondialdehyde (MDA)-protein adducts and SOD1 levels were higher in tumor and nontumor samples of LC-COPD than in LC. In tumors compared with nontumors, SOD2 protein content was greater, whereas catalase levels were decreased in both LC and LC-COPD patients. Blood superoxide anion levels, protein carbonylation and nitration were greater in LC and LC-COPD patients than in the controls, and in the latter patients compared with the former. Systemic superoxide anion, protein carbonyls and nitrotyrosine above specific cutoff values best identified underlying COPD among all patients. Smoking did not influence the study results. A differential expression profile of oxidative stress markers exists in blood and, to a lesser extent, in the tumors of LC-COPD patients. These findings suggest that systemic oxidative stress and lung antioxidants (potential biomarkers) may predispose patients with chronic respiratory diseases to a higher risk for LC., This study has been supported with funding by SEPAR 2008, FUCAP 2009, FUCAP 2011, FUCAP 2012, FIS 11/02029 (FEDER), FIS 14/00713 (FEDER), SAF2011-26908, and CIBERES (Instituto de Salud Carlos III).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ring finger protein 1 (MuRF1).

  • Jaitovich, Ariel
  • Angulo, Martín
  • Lecuona, Emilia
  • Dada, Laura A.
  • Welch, Lynn C.
  • Cheng, Yuan
  • Gusarova, Galina
  • Ceco, Ermelinda
  • Liu, Chang
  • Shigemura, Masahiko
  • Barreiro Portela, Esther
  • Patterson, Cam
  • Nader, Gustavo A.
  • Sznajder, Jacob I.
Patients with chronic obstructive pulmonary disease, acute lung injury, and critical care illness may develop hypercapnia. Many of these patients often have muscle dysfunction which increases morbidity and impairs their quality of life. Here, we investigated whether hypercapnia leads to skeletal muscle atrophy. Mice exposed to high CO2 had decreased skeletal muscle wet weight, fiber diameter, and strength. Cultured myotubes exposed to high CO2 had reduced fiber diameter, protein/DNA ratios, and anabolic capacity. High CO2 induced the expression of MuRF1 in vivo and in vitro, whereas MuRF1(-/-) mice exposed to high CO2 did not develop muscle atrophy. AMP-activated kinase (AMPK), a metabolic sensor, was activated in myotubes exposed to high CO2, and loss-of-function studies showed that the AMPKα2 isoform is necessary for muscle-specific ring finger protein 1 (MuRF1) up-regulation and myofiber size reduction. High CO2 induced AMPKα2 activation, triggering the phosphorylation and nuclear translocation of FoxO3a, and leading to an increase in MuRF1 expression and myotube atrophy. Accordingly, we provide evidence that high CO2 activates skeletal muscle atrophy via AMPKα2-FoxO3a-MuRF1, which is of biological and potentially clinical significance in patients with lung diseases and hypercapnia., This work was supported in part by National Institutes of Health Grants CA060553 (to the Robert H. Lurie Comprehensive Cancer Center Cores: Center for Advanced Microscopy Center, Genomics Core, and Mouse Phenotyping and Histology Laboratory), HL-85534, HL-71643, and HL-T32–76139. This work was also supported by Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) and Grants FIS 11/02029 and FIS 12/02534 (Instituto de Salud Carlos III), Spain and SAF- 2011-26908 from Ministry of Competitiveness, Spain
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights

  • Barreiro Portela, Esther
  • Bustamante, Víctor
  • Curull Serrano, Víctor
  • Gea Guiral, Joaquim
  • Lopez-Campos, Jose Luis
  • Muñoz, Xavier
Lung cancer (LC) has become one of the leading causes of preventable death in the last few decades. Cigarette smoking (CS) stays as the main etiologic factor of LC despite that many other causes such as occupational exposures, air pollution, asbestos, or radiation have also been implicated. Patients with chronic obstructive pulmonary disease (COPD), which also represents a major cause of morbidity and mortality in developed countries, exhibit a significantly greater risk of LC. The study of the underlying biological mechanisms that may predispose patients with chronic respiratory diseases to a higher incidence of LC has also gained much attention in the last few years. The present review has been divided into three major sections in which different aspects have been addressed: (I) relevant etiologic agents of LC; (II) studies confirming the hypothesis that COPD patients are exposed to a greater risk of developing LC; and (III) evidence on the most relevant underlying biological mechanisms that support the links between COPD and LC. Several carcinogenic agents have been described in the last decades but CS remains to be the leading etiologic agent in most geographical regions in which the incidence of LC is very high. Growing evidence has put the line forward the implications of COPD and especially of emphysema in LC development. Hence, COPD represents a major risk factor of LC in patients. Different avenues of research have demonstrated the presence of relevant biological mechanisms that may predispose COPD patients to develop LC. Importantly, the so far identified biological mechanisms offer targets for the design of specific therapeutic strategies that will further the current treatment options for patients with LC. Prospective screening studies, in which patients with COPD should be followed up for several years will help identify biomarkers that may predict the risk of LC among these patients., SEPAR 2008, FUCAP 2009, FUCAP 2011, FUCAP 2012, FIS 11/02029 (FEDER), FIS 14/00713 (FEDER), SAF2011-26908, and CIBERES (Instituto de Salud Carlos III) (Spain) have contributed to fund part of the research described in the review.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Chronic obstructive pulmonary disease (COPD) will be a major leading cause of death worldwide in the near future. Weakness and atrophy of the quadriceps are associated with a significantly poorer prognosis and increased mortality in COPD. Despite that skeletal muscle dysfunction may affect both respiratory and limb muscle groups in COPD, the latter are frequently more severely affected. Therefore, muscle dysfunction in COPD is a common systemic manifestation that should be evaluated on routine basis in clinical settings. In the present review, several aspects of COPD muscle dysfunction are being reviewed, with special emphasis on the underlying biological mechanisms. Figures on the prevalence of COPD muscle dysfunction and the most relevant etiologic contributors are also provided. Despite that ongoing research will shed light into the contribution of additional mechanisms to COPD muscle dysfunction, current knowledge points toward the involvement of a wide spectrum of cellular and molecular events that are differentially expressed in respiratory and limb muscles. Such mechanisms are thoroughly described in the article. The contribution of epigenetic events on COPD muscle dysfunction is also reviewed. We conclude that in view of the latest discoveries, from now, on new avenues of research should be designed to specifically target cellular mechanisms and pathways that impair muscle mass and function in COPD using pharmacological strategies and/or exercise training modalities., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: CIBERES, FIS 11/02029 (FEDER), FIS 14/ 00713 (FEDER), SAF-2011-26908, SAF-2014-54371-R, SEPAR 2010, SEPAR 2014, FUCAP 2009, FUCAP 2011, FUCAP 2012, and Marato´ TV3 (MTV3-07-1010) (Spain) have contributed to support part of the research described in this review.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Do epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease?

  • Puig Vilanova, Ester, 1987-
  • Ausín Herrero, Pilar, 1974-
  • Martínez-Llorens, Juana Mª
  • Gea Guiral, Joaquim
  • Barreiro Portela, Esther
Muscle dysfunction is a major comorbidity in Chronic Obstructive Pulmonary Disease (COPD). Several biological mechanisms including epigenetic events regulate muscle mass and function in models of muscle atrophy. Investigations conducted so far have focused on the elucidation of biological mechanisms involved in muscle dysfunction in advanced COPD. We assessed whether the epigenetic profile may be altered in the vastus lateralis of patients with mild COPD, normal body composition, and mildly impaired muscle function and exercise capacity. In vastus lateralis (VL) of mild COPD patients with well-preserved body composition and in healthy age-matched controls, expression of DNA methylation, muscle-enriched microRNAs, histone acetyltransferases (HTAs) and deacetylases (HDACs), protein acetylation, small ubiquitin-related modifier (SUMO) ligases, and muscle structure were explored. All subjects were clinically evaluated. Compared to healthy controls, in the VL of mild COPD patients, muscle function and exercise capacity were moderately reduced, DNA methylation levels did not differ, miR-1 expression levels were increased and positively correlated with both forced expiratory volume in one second (FEV1) and quadriceps force, HDAC4 protein levels were increased, and muscle fiber types and sizes were not different. Moderate skeletal muscle dysfunction is a relevant feature in patients with mild COPD and preserved body composition. Several epigenetic events are differentially expressed in the limb muscles of these patients, probably as an attempt to counterbalance the underlying mechanisms that alter muscle function and mass. The study of patients at early stages of their disease is of interest as they are a target for timely therapeutic interventions that may slow down the course of the disease and prevent the deleterious effects of major comorbidities., This study has been supported by Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES); Fondo de Investigaciones Sanitarias (FIS) 11/02029; FIS 12/02534; SAF-2011-26908; 2009-SGR-393; Sociedad Española de Neumología y Cirugía Torácica (SEPAR) 2009; Fundació Catalana de Pneumologia (FUCAP) 2011; FUCAP 2012; and Marató TV3 (MTV3-07-1010) (Spain). Dr. Esther Barreiro was a recipient of the European Respiratory Society (ERS) COPD Research Award 2008
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Network medicine analysis of COPD multimorbidities

  • Grosdidier, Solène
  • Ferrer, Antoni-Lluc, 1942-
  • Faner, Rosa
  • Piñero González, Janet, 1977-
  • Roca, Josep
  • García Cosio, Borja
  • Agustí García-Navarro, Àlvar
  • Gea Guiral, Joaquim
  • Sanz, Ferran
  • Furlong, Laura I., 1971-
Background: Patients with chronic obstructive pulmonary disease (COPD) often suffer concomitant disorders that worsen significantly their health status and vital prognosis. The pathogenic mechanisms underlying COPD multimorbidities are not completely understood, thus the exploration of potential molecular and biological linkages between COPD and their associated diseases is of great interest. Methods: We developed a novel, unbiased, integrative network medicine approach for the analysis of the diseasome, interactome, the biological pathways and tobacco smoke exposome, which has been applied to the study of 16 prevalent COPD multimorbidities identified by clinical experts. Results: Our analyses indicate that all COPD multimorbidities studied here are related at the molecular and biological level, sharing genes, proteins and biological pathways. By inspecting the connections of COPD with their associated diseases in more detail, we identified known biological pathways involved in COPD, such as inflammation, endothelial dysfunction or apoptosis, serving as a proof of concept of the methodology. More interestingly, we found previously overlooked biological pathways that might contribute to explain COPD multimorbidities, such as hemostasis in COPD multimorbidities other than cardiovascular disorders, and cell cycle pathway in the association of COPD with depression. Moreover, we also observed similarities between COPD multimorbidities at the pathway level, suggesting common biological mechanisms for different COPD multimorbidities. Finally, chemicals contained in the tobacco smoke target an average of 69% of the identified proteins participating in COPD multimorbidities. Conclusions: The network medicine approach presented here allowed the identification of plausible molecular links between COPD and comorbid diseases, and showed that many of them are targets of the tobacco exposome, proposing new areas of research for understanding the molecular underpinning of COPD multimorbidities., This work was supported by the Instituto de Salud Carlos III FEDER (CP10/00524 and PI13/00082), COMBIOMED and SAF2011-26908 grants
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular and biological pathways of skeletal muscle dysfunction in chronic obstructive pulmonary disease.

  • Barreiro Portela, Esther
  • Gea Guiral, Joaquim
Chronic obstructive pulmonary disease (COPD) will be a major leading cause of death worldwide in the near future. Weakness and atrophy of the quadriceps are associated with a significantly poorer prognosis and increased mortality in COPD. Despite that skeletal muscle dysfunction may affect both respiratory and limb muscle groups in COPD, the latter are frequently more severely affected. Therefore, muscle dysfunction in COPD is a common systemic manifestation that should be evaluated on routine basis in clinical settings. In the present review, several aspects of COPD muscle dysfunction are being reviewed, with special emphasis on the underlying biological mechanisms. Figures on the prevalence of COPD muscle dysfunction and the most relevant etiologic contributors are also provided. Despite that ongoing research will shed light into the contribution of additional mechanisms to COPD muscle dysfunction, current knowledge points toward the involvement of a wide spectrum of cellular and molecular events that are differentially expressed in respiratory and limb muscles. Such mechanisms are thoroughly described in the article. The contribution of epigenetic events on COPD muscle dysfunction is also reviewed. We conclude that in view of the latest discoveries, from now, on new avenues of research should be designed to specifically target cellular mechanisms and pathways that impair muscle mass and function in COPD using pharmacological strategies and/or exercise training modalities., The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: CIBERES, FIS 11/02029 (FEDER), FIS 14/ 00713 (FEDER), SAF-2011-26908, SAF-2014-54371-R, SEPAR 2010, SEPAR 2014, FUCAP 2009, FUCAP 2011, FUCAP 2012, and Marato´ TV3 (MTV3-07-1010) (Spain) have contributed to support part of the research described in this review.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

High CO2 levels cause skeletal muscle atrophy via AMP-activated kinase (AMPK), FoxO3a protein, and muscle-specific Ring finger protein 1 (MuRF1).

  • Jaitovich, Ariel
  • Angulo, Martín
  • Lecuona, Emilia
  • Dada, Laura A.
  • Welch, Lynn C.
  • Cheng, Yuan
  • Gusarova, Galina
  • Ceco, Ermelinda
  • Liu, Chang
  • Shigemura, Masahiko
  • Barreiro Portela, Esther
  • Patterson, Cam
  • Nader, Gustavo A.
  • Sznajder, Jacob I.
Patients with chronic obstructive pulmonary disease, acute lung injury, and critical care illness may develop hypercapnia. Many of these patients often have muscle dysfunction which increases morbidity and impairs their quality of life. Here, we investigated whether hypercapnia leads to skeletal muscle atrophy. Mice exposed to high CO2 had decreased skeletal muscle wet weight, fiber diameter, and strength. Cultured myotubes exposed to high CO2 had reduced fiber diameter, protein/DNA ratios, and anabolic capacity. High CO2 induced the expression of MuRF1 in vivo and in vitro, whereas MuRF1(-/-) mice exposed to high CO2 did not develop muscle atrophy. AMP-activated kinase (AMPK), a metabolic sensor, was activated in myotubes exposed to high CO2, and loss-of-function studies showed that the AMPKα2 isoform is necessary for muscle-specific ring finger protein 1 (MuRF1) up-regulation and myofiber size reduction. High CO2 induced AMPKα2 activation, triggering the phosphorylation and nuclear translocation of FoxO3a, and leading to an increase in MuRF1 expression and myotube atrophy. Accordingly, we provide evidence that high CO2 activates skeletal muscle atrophy via AMPKα2-FoxO3a-MuRF1, which is of biological and potentially clinical significance in patients with lung diseases and hypercapnia., This work was supported in part by National Institutes of Health Grants CA060553 (to the Robert H. Lurie Comprehensive Cancer Center Cores: Center for Advanced Microscopy Center, Genomics Core, and Mouse Phenotyping and Histology Laboratory), HL-85534, HL-71643, and HL-T32–76139. This work was also supported by Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) and Grants FIS 11/02029 and FIS 12/02534 (Instituto de Salud Carlos III), Spain and SAF- 2011-26908 from Ministry of Competitiveness, Spain
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Redox imbalance in lung cancer of patients with underlying chronic respiratory conditions

  • Mateu Jiménez, Mercè, 1990-
  • Sánchez-Font, Albert
  • Rodríguez-Fuster, Alberto
  • Aguiló Espases, Rafael
  • Pijuan Andujar, Lara
  • Fermoselle Pérez, Clara, 1985-
  • Gea Guiral, Joaquim
  • Curull Serrano, Víctor
  • Barreiro Portela, Esther
Chronic respiratory diseases such as obstructive pulmonary disease (COPD) and oxidative stress may underlie lung cancer (LC). We hypothesized that the profile of oxidative and antioxidant events may differ in lung tumors and blood compartments of patients with non-small cell LC (NSCLC) with and without COPD. Redox markers (immunoblotting, ELISA, chemiluminescence, 2D electrophoresis and proteomics) were analyzed in blood samples of 17 control subjects and 80 LC patients (59 LC-COPD and 21 LC) and lung specimens (tumor and nontumor) from those undergoing thoracotomy (35 patients: 23 LC-COPD and 12 LC). As smoking history was more prevalent in LC-COPD patients, these were further analyzed post hoc as heavy and moderate smokers (cutoff, 60 pack-years). Malondialdehyde (MDA)-protein adducts and SOD1 levels were higher in tumor and nontumor samples of LC-COPD than in LC. In tumors compared with nontumors, SOD2 protein content was greater, whereas catalase levels were decreased in both LC and LC-COPD patients. Blood superoxide anion levels, protein carbonylation and nitration were greater in LC and LC-COPD patients than in the controls, and in the latter patients compared with the former. Systemic superoxide anion, protein carbonyls and nitrotyrosine above specific cutoff values best identified underlying COPD among all patients. Smoking did not influence the study results. A differential expression profile of oxidative stress markers exists in blood and, to a lesser extent, in the tumors of LC-COPD patients. These findings suggest that systemic oxidative stress and lung antioxidants (potential biomarkers) may predispose patients with chronic respiratory diseases to a higher risk for LC., This study has been supported with funding by SEPAR 2008, FUCAP 2009, FUCAP 2011, FUCAP 2012, FIS 11/02029 (FEDER), FIS 14/00713 (FEDER), SAF2011-26908, and CIBERES (Instituto de Salud Carlos III).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights

  • Barreiro Portela, Esther
  • Bustamante, Víctor
  • Curull Serrano, Víctor
  • Gea Guiral, Joaquim
  • Lopez-Campos, Jose Luis
  • Muñoz, Xavier
Lung cancer (LC) has become one of the leading causes of preventable death in the last few decades. Cigarette smoking (CS) stays as the main etiologic factor of LC despite that many other causes such as occupational exposures, air pollution, asbestos, or radiation have also been implicated. Patients with chronic obstructive pulmonary disease (COPD), which also represents a major cause of morbidity and mortality in developed countries, exhibit a significantly greater risk of LC. The study of the underlying biological mechanisms that may predispose patients with chronic respiratory diseases to a higher incidence of LC has also gained much attention in the last few years. The present review has been divided into three major sections in which different aspects have been addressed: (I) relevant etiologic agents of LC; (II) studies confirming the hypothesis that COPD patients are exposed to a greater risk of developing LC; and (III) evidence on the most relevant underlying biological mechanisms that support the links between COPD and LC. Several carcinogenic agents have been described in the last decades but CS remains to be the leading etiologic agent in most geographical regions in which the incidence of LC is very high. Growing evidence has put the line forward the implications of COPD and especially of emphysema in LC development. Hence, COPD represents a major risk factor of LC in patients. Different avenues of research have demonstrated the presence of relevant biological mechanisms that may predispose COPD patients to develop LC. Importantly, the so far identified biological mechanisms offer targets for the design of specific therapeutic strategies that will further the current treatment options for patients with LC. Prospective screening studies, in which patients with COPD should be followed up for several years will help identify biomarkers that may predict the risk of LC among these patients., SEPAR 2008, FUCAP 2009, FUCAP 2011, FUCAP 2012, FIS 11/02029 (FEDER), FIS 14/00713 (FEDER), SAF2011-26908, and CIBERES (Instituto de Salud Carlos III) (Spain) have contributed to fund part of the research described in the review.